Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals.
Ontology highlight
ABSTRACT: The global efforts in the past year have led to the discovery of nearly 200 drug repurposing candidates for COVID-19. Gaining more insights into their mechanisms of action could facilitate a better understanding of infection and the development of therapeutics. Leveraging large-scale drug-induced gene expression profiles, we found 36% of the active compounds regulate genes related to cholesterol homeostasis and microtubule cytoskeleton organization. Following bioinformatics analyses revealed that the expression of these genes is associated with COVID-19 patient severity and has predictive power on anti-SARS-CoV-2 efficacy in vitro. Monensin, a top new compound that regulates these genes, was further confirmed as an inhibitor of SARS-CoV-2 replication in Vero-E6 cells. Interestingly, drugs
SUBMITTER: Xing J
PROVIDER: S-EPMC8344595 | biostudies-literature | 2021 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA